Ashkon Software



CLRBW - Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. logo Cellectar Biosciences, Inc. (CLRBW) is a clinical-stage biopharmaceutical company that is focused on the development of targeted cancer therapies. The company's proprietary phospholipid drug conjugate (PDC) platform technology allows for the delivery of therapeutic agents directly to cancer cells, while minimizing toxicity to healthy cells.

Cellectar Biosciences' lead drug candidate is CLR 131, a PDC-based radiotherapeutic that is being developed for the treatment of a variety of cancers, including multiple myeloma and certain types of lymphoma. The drug works by delivering a radioactive payload directly to cancer cells, while sparing healthy cells from radiation damage.

In addition to CLR 131, Cellectar Biosciences is also developing a pipeline of other PDC-based therapies for the treatment of cancer. The company's pipeline includes CLR 125, a PDC-based imaging agent for use in cancer detection, and CLR 1900, a PDC-based therapeutic that is being developed for the treatment of pediatric cancers.

Cellectar Biosciences was founded in 2002 and is headquartered in Florham Park, New Jersey. The company has a small team of employees and collaborates with academic and industry partners to advance its drug development programs. As of 2021, the company is focused on advancing CLR 131 through clinical trials and seeking regulatory approval for the drug. Cellectar Biosciences faces significant competition from other companies developing cancer therapies, particularly in the areas of radiotherapeutics and targeted




Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer